By Josh White
Date: Friday 15 Mar 2024
(Sharecast News) - Biotechnology company Sareum announced on Friday that the European Patent Office had issued a notice of allowance for a patent concerning SDC‐1801, its primary TYK2/JAK1 kinase inhibitor currently undergoing clinical trials in Australia.
By Josh White
Date: Thursday 15 Feb 2024
(Sharecast News) - Sareum announced significant milestones in its phase 1a clinical trial for SDC-1801, its lead programme aimed at addressing autoimmune diseases such as psoriasis, on Thursday.
By Benjamin Chiou
Date: Tuesday 02 Jan 2024
(Sharecast News) - Shares in AIM-listed biotech group Sareum jumped by a fifth on Tuesday after its co-development partner for cancer treatment SRA737 signed a commercialisation licence agreement with a US biopharma company.
Currency | UK Pounds |
Share Price | 26.25p |
Change Today | 0.000p |
% Change | 0.00 % |
52 Week High | 142.50 |
52 Week Low | 10.25 |
Volume | 2,040,757 |
Shares Issued | 106.84m |
Market Cap | £28.05m |
RiskGrade | 594 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Strong Buy | 1 |
Buy | 0 |
Neutral | 0 |
Sell | 0 |
Strong Sell | 0 |
Total | 1 |
No dividends found |
Time | Volume / Share Price |
17:06 | 146,274 @ 26.25p |
16:29 | 3,703 @ 26.05p |
16:22 | 3,725 @ 26.00p |
16:20 | 19,261 @ 26.00p |
16:17 | 2,500 @ 26.35p |
You are here: research